Not FDA-approved1Evidence: Smaller human trialsSkin · Tissue repair and wound healing

GHK-Cu1,2

Also called Copper tripeptide-1, GHK copper2

Key takeaway

GHK-Cu, also called copper tripeptide-1, is a small peptide bound to copper that is used in skin-care research.2,5 None of the sources reviewed here reports an FDA approval of GHK-Cu. Since May 2026, FDA has listed GHK-Cu, except in injected forms, as under evaluation for the list of substances pharmacies may use in compounding.1 FDA lists injected GHK-Cu among compounding substances that may present significant safety risks, noting possible immune reactions and limited human data.3 GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.7

GHK-Cu at a glance

What it isA copper-binding tripeptide, a chain of three amino acids (glycyl-histidyl-lysine) bound to copper, recorded by FDA as copper tripeptide-1.2,4
FDA statusNo FDA approval is reported in the sources reviewed here. FDA lists GHK-Cu, except in injected forms, in category 1 (under evaluation) for the 503A compounding list, and lists injected GHK-Cu among withdrawn nominations with safety concerns.1,3
Human evidenceTwo randomized studies of copper-peptide skin and wound products, one of them very small, with mixed results.4,5
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is GHK-Cu?

GHK-Cu is a complex of copper with a three-amino-acid peptide, glycyl-L-histidyl-L-lysine. FDA’s substance registry records it as copper tripeptide-1.2,4

Published human studies have tested it in wound-care and skin-care products.4,5

How is GHK-Cu thought to work?

GHK-Cu has been studied for wound healing and skin repair, but the sources reviewed here do not establish how it works in people.4,5

FDA’s safety-risk page notes that injected GHK-Cu could provoke immune reactions because of possible clumping of the peptide and peptide-related impurities.3

What do human studies show?

In a multicenter randomized study in people with diabetic foot ulcers, the authors reported greater ulcer closure and fewer infections with a copper-peptide gel than with an inactive gel in one comparison. The abstract does not give the total number of participants.4

In a small randomized study after laser skin resurfacing, 13 people completed 12 weeks of skin care with or without GHK-Cu. Blinded and computer assessments found no significant differences in redness, wrinkles or overall skin quality, although participants rated their skin better with GHK-Cu.5

FDA states that there are limited human data to inform the safety of injected GHK-Cu.3

What the evidence base contains

  • Controlled human trial A multicenter, randomized, evaluator-blinded study comparing a copper-peptide gel with an inactive gel, alongside standard wound care, in people with diabetic foot ulcers. The published abstract does not give the total number of participants.4
  • Controlled human trial A small randomized study in which 13 people completed skin-care routines with or without GHK-Cu after laser skin resurfacing and were followed for 12 weeks.5

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is GHK-Cu FDA-approved?

None of the sources reviewed here reports an approval of GHK-Cu by FDA. FDA’s records reviewed here concern its status for pharmacy compounding.1,3

FDA’s list of substances nominated under section 503A, updated May 14, 2026, places GHK-Cu, except in injected forms, back in category 1, meaning under evaluation. FDA explains that it had removed GHK-Cu on April 22, 2026 after nominations were withdrawn, but that one nominator clarified on May 5, 2026 that it meant to withdraw only the injected form.1

The same list states that FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu should be added to the 503A bulks list.1

FDA’s compounding safety-risk page, current as of April 22, 2026, lists injected GHK-Cu among substances whose nominations were withdrawn, citing possible immune reactions and limited human safety data.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not among them.6,7

Timeline

  1. Results of a randomized study of a copper-peptide gel in diabetic foot ulcers are published.4
  2. Results of a small randomized study of GHK-Cu skin care after laser resurfacing are published.5
  3. FDA removes GHK-Cu from category 1 after nominations are withdrawn, and its safety-risk page lists injected GHK-Cu among withdrawn nominations.1,3
  4. FDA restores GHK-Cu, except in injected forms, to category 1 of its 503A nominations list.1

What is still unknown?

Whether GHK-Cu has a clinical benefit: the two randomized studies reviewed here had mixed results, and one was very small.4,5

The safety of injected GHK-Cu, for which FDA says human data are limited.3

What FDA will decide after consulting its advisory committee, which it said it intends to do before the end of February 2027.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for GHK-Cu: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for GHK-Cu are the records PeptideScanner has selected and published, not every registration or paper about GHK-Cu. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; under FDA review for pharmacy compounding by non-injectable routes. Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected human reports cover topical wound and post-laser skin care, plus a multi-ingredient intradermal hair formulation containing copper tripeptide-1. Formulation and route are kept separate. This is not an exhaustive review of GHK or GHK-Cu.↗↗↗

What the reviewed sources report

The selected topical studies had different findings: the ulcer study reported improved closure, while the small post-laser study found no objective advantage in erythema or skin appearance. The uncontrolled hair study cannot attribute changes to GHK-Cu alone or establish the safety of other injected formulations.↗↗↗

What remains unresolved?

  • Which outcomes are supported by adequately controlled studies of a clearly identified GHK-Cu formulation?↗↗↗
  • How do route, co-ingredients, study size, and follow-up limit what can be concluded about benefits and harms?↗↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about GHK-Cu?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Three selected human reports cover topical wound and post-laser skin care, plus a multi-ingredient intradermal hair formulation containing copper tripeptide-1. Formulation and route are kept separate. This is not an exhaustive review of GHK or GHK-Cu.123

Bottom line from this bounded source set

The selected topical studies had different findings: the ulcer study reported improved closure, while the small post-laser study found no objective advantage in erythema or skin appearance. The uncontrolled hair study cannot attribute changes to GHK-Cu alone or establish the safety of other injected formulations.123

Reviewed study record

Diabetic ulcers: topical copper-peptide formulation

Design

A multicenter randomized, evaluator-blinded study compared a topical copper-peptide gel with vehicle alongside standardized wound care.1

Population

The report concerns patients with diabetic neuropathic ulcers; the PubMed abstract does not state the total sample size.1

Outcomes reported

The authors reported greater plantar-ulcer area closure and fewer infections in a selected immediate-treatment comparison. These are results for the studied topical formulation and wound-care setting.1

Limitations

Subgroup and treatment-timing comparisons require full-text assessment. The abstract alone does not establish overall healing benefit, general safety, or effectiveness by other routes.1

Reviewed study record

Post-laser skin care: small randomized comparison

Design

Patients receiving carbon-dioxide laser resurfacing were randomized to skin-care regimens with or without GHK-Cu.2

Population

Thirteen patients completed the study; outcomes were assessed through 12 weeks.2

Outcomes reported

Blinded and computer assessments found no significant between-group improvement in erythema resolution, wrinkles, or overall skin quality. Patient-reported skin-quality improvement favored the GHK-Cu regimen.2

Limitations

The sample was small, and subjective and objective findings differed. These findings do not establish a general anti-aging effect or apply to injectable use.2

Reviewed study record

Hair research: multi-ingredient formulation

Design

An open-label, single-arm pilot evaluated an intradermal formulation containing several growth factors and copper tripeptide-1.3

Population

The authors reported treating 1,000 patients with hair loss.3

Outcomes reported

The report described improvements in hair assessments and patient impressions and reported that treatment was well tolerated.3

Limitations

There was no control group and the formulation contained multiple active ingredients. The study cannot isolate a GHK-Cu effect or establish safety for GHK-Cu injections alone.3

Reviewed source set

  1. PubMed · 17147644Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. ↗PubMed PMID 17147644 · EFetch XML reviewed 2026-09-15 · payload SHA-256 574ec25695392a76cb7f4eba0428dbc9f98dafaf617032e712f1374e7421ae0b
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1046/j.1524-475x.1994.20406.x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 16847171Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. ↗PubMed PMID 16847171 · EFetch XML reviewed 2026-09-15 · payload SHA-256 dca52781a78cb830f560d30b3164dee33b925deef3e220a9679a5ff86e2d73cc
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1001/archfaci.8.4.252. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 29482481Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. ↗PubMed PMID 29482481 · EFetch XML reviewed 2026-09-15 · payload SHA-256 ec015b07b2826a8a8516637579d063394b2dd2b509ac5c0c15b0e8efbcb706b2
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1080/14764172.2018.1439965. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 2

FDA’s records distinguish non-injectable GHK-Cu

The May 14, 2026 nominations list restores GHK-Cu excluding injectable routes to Category 1, meaning under evaluation. FDA explains that a nominator clarified its withdrawal applied only to the injectable route. FDA PDF pp. 1, 2, 3 ↗

More findings and the sources behind them

Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Earlier dated FDA and registry findings remain separately attributed below.

Injectable concerns remain separately documented

FDA’s safety page lists injectable GHK-Cu among withdrawn nominations, with concerns about aggregation, peptide impurities and immune responses, and limited human safety data. It should not be described as currently in Category 2 on that basis. FDA source ↗

What the next review could clarify

The May list announces an intention to consult the advisory committee before the end of February 2027 about potential inclusion on the 503A bulks list. An announced consultation is not a completed review or a finding of effectiveness. FDA PDF pp. 1, 2, 3 ↗

A registered topical wound study is now identifiable

NCT07437586 describes a phase 2 study of topical GHK-Cu gel in healthy adults. In the February 27, 2026 registry update it is recruiting, with estimated enrollment of 60 and no posted summary results. NCT07437586 ↗

The comparison is within each participant

Each participant is to have two standardized wounds, one assigned to GHK-Cu gel and one to vehicle gel. This paired design means wound counts are not counts of independent people; it is not an injectable study. NCT07437586 ↗

The primary endpoint is complete wound closure

The registered primary outcome is time to complete re-epithelialization, assessed through day 21 using blinded examination and photographs. The entry describes what investigators plan to measure, not an observed acceleration of healing. NCT07437586 ↗

The selected population excludes impaired-healing conditions

The trial excludes diabetes, peripheral vascular disease and other conditions that could impair wound healing. Even eventual positive results in this population would not automatically establish benefit in chronic ulcers or with injected GHK-Cu. NCT07437586 ↗

What remains to be checked

  • Check later results and eligibility changes for NCT07437586; registration alone is not a clinical finding.
  • Appraise topical human reports and FDA follow-up separately from injectable claims and product mixtures.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA 503A nominations list, May 14, 2026 ↗

    Source dated 2026-05-14; retrieved 2026-09-16.

    • GHK-Cu correction and Category 1 entry · PDF pp. 1, 2, 3 of 7

    SHA-256: 94f3353f1bdf65ac1800dfe747c5efdc33fa542f1ba40344a31e2fe286614415

  • FDA bulk-substance safety concerns ↗

    Source dated 2026-04-22; retrieved 2026-09-16.

    • Bulk drug substances nominated but withdrawn: GHK-Cu (for injectable routes of administration)

    SHA-256: 1a43f6d8b9da6b1fb5b2da83130882ec18e255f862c773d4cb636d67061c41cf

  • Topical GHK-Cu Gel for Acute Skin Wound Healing ↗

    Source dated 2026-02-27; retrieved 2026-09-19.

    • protocolSection.identificationModule, designModule and armsInterventionsModule
    • protocolSection.eligibilityModule and armsInterventionsModule
    • protocolSection.outcomesModule
    • protocolSection.statusModule; presence or absence of resultsSection in retrieved record

    SHA-256: c57f70defe49f90fc8b52b29a993f517a64f5ba334ae0a74250855355a452421

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

306 retrieved · 3 included · 0 excluded · 303 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"GHK-Cu"[Title/Abstract] OR "GHK"[Title/Abstract] OR "copper tripeptide"[Title/Abstract] OR "glycyl-l-histidyl-l-lysine copper"[Title/Abstract] OR "glycyl-l-histidyl-l-lysine"[Title/Abstract] OR "Copper tripeptide-1"[Title/Abstract] OR "GHK copper"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:30.585133+00:00 · HTTP 200 · SHA-256 e05452e139952df2d1da6bd1122e5d1731302176889eae0d8ba0de04345e6769.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
  • GHK, copper complexes, sequence names and topical mixtures require separate identity and formulation decisions. A name hit is not evidence of injected GHK-Cu use.

Showing 25 of 306 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 29482481 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: ghk-cu-PMID29482481-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 ec015b07b2826a8a8516637579d063394b2dd2b509ac5c0c15b0e8efbcb706b2.

  2. PubMed 16847171 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: ghk-cu-PMID16847171-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 dca52781a78cb830f560d30b3164dee33b925deef3e220a9679a5ff86e2d73cc.

  3. PubMed 17147644 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: ghk-cu-PMID17147644-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 574ec25695392a76cb7f4eba0428dbc9f98dafaf617032e712f1374e7421ae0b.

  4. PubMed 42712263 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42635865 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42619529 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42586657 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42578445 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42575238 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42573538 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42510549 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42404628 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42354780 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42320090 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42245779 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42193036 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42185208 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42123471 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42084774 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42058630 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42047624 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42041438 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42032121 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42021992 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42016822 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"GHK-CU"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:15.024655+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["GHK-Cu", "Copper tripeptide-1", "GHK copper"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["GHK-Cu", "Copper tripeptide-1", "GHK copper"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["GHK-Cu", "Copper tripeptide-1", "GHK copper"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          2 retrieved · 0 included · 0 excluded · 2 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "GHK-Cu" OR "Copper tripeptide-1" OR "GHK copper" OR "glycyl-l-histidyl-l-lysine copper"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:25:25.189570+00:00 · HTTP 200 · SHA-256 95722d778294c081535ff6816d33d6296ff98d54a417206f92b2dc27c3e9ad67.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          1. ClinicalTrials.gov NCT07437586 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          2. ClinicalTrials.gov NCT07706361 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of GHK-Cu?

          Not FDA-approved; under FDA review for pharmacy compounding by non-injectable routes. Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

          The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          1
          Source years
          7
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Collection changes

          What did PeptideScanner add most recently?

          1. Literature metadata · added November 14, 2026

            GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.↗Source date September 29, 2026
          2. Literature metadata · added August 13, 2026

            Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?↗Source date May 21, 2025
          3. Literature metadata · added August 13, 2026

            Phenothiazine-Based Cu(II)-Selective Fluorescent Sensor: GHK-Cu Sensing Applications.↗Source date November 3, 2023

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to GHK-Cu?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          17Selected dated records
          24Connected citations
          7Populated source years2015–2026
          1/4Record lanes present

          Registered human studies

          Trial composition

          0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

          PubMed bibliography

          Publication composition

          5 of 17 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Publication typesJournal Article 5Review 2

          Bibliography fields unavailable here for 12 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          0
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          17

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Source records by collection · 17 dated records

          Research hub

          Explore the GHK-Cu evidence record

          Open all 17 records →
          17Dated records
          1Evidence type
          17Cited public sources
          7Source years

          Change ledger

          Recently changed for GHK-Cu

          Open all 19 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          GHK-Cu profile

          We added a plain-language reader guide with cited answers, re-checked FDA’s May 2026 503A nominations list, added FDA’s compounding safety-risk page and two randomized studies from our human evidence review, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include GHK-Cu.

          PeptideScanner change date
          November 14, 2026
          Evidence lane
          Profile
          Record added

          GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.

          PubMed lists PMID 42797253 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2026-08-27 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

          PeptideScanner change date
          November 14, 2026
          Cited source date
          September 29, 2026
          Evidence lane
          Literature metadata
          Record added

          In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer.

          PubMed lists PMID 31815212 in ACS omega as Journal Article, with publication-date metadata of 2019-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

          PeptideScanner change date
          August 13, 2026
          Cited source date
          October 20, 2023
          Evidence lane
          Literature metadata

          Official-source collections

          Source records for GHK-Cu

          Open the full research atlas →

          Evidence types

          Coverage by source year

          Selected records span June 2, 2015 to September 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • U.S. Food and Drug Administration1
          • U.S. Department of Health and Human Services6
          Dated updates connected to this profile · 17

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Literature metadata

            GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.↗

            PubMed lists PMID 42797253 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2026-08-27 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          2. Literature metadata

            PubMed record PMID 42510549↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42510549 at 2026-08-10T10:49:10.805Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          3. Literature metadata

            PubMed record PMID 39451062↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 39451062 at 2026-08-10T18:13:36.036Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2024-10-25. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          4. Literature metadata

            PubMed record PMID 42084774↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42084774 at 2026-08-10T18:13:48.846Z. PubMed recorded a metadata revision date of 2026-07-16 and an Entrez history date of 2026-05-05. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          5. Literature metadata

            PubMed record PMID 41997403↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 41997403 at 2026-08-10T18:13:46.888Z. PubMed recorded a metadata revision date of 2026-07-15 and an Entrez history date of 2026-04-17. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          6. Literature metadata

            PubMed record PMID 42041438↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42041438 at 2026-08-10T18:13:48.795Z. PubMed recorded a metadata revision date of 2026-07-15 and an Entrez history date of 2026-04-27. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          7. Literature metadata

            PubMed record PMID 42245779↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42245779 at 2026-07-30T16:14:18.092Z. PubMed recorded a metadata revision date of 2026-06-29 and an Entrez history date of 2026-06-05. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          8. Literature metadata

            PubMed record PMID 37062921↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 37062921 at 2026-07-30T16:31:12.094Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2023-04-17. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗

          9. Literature metadata

            Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?↗

            PubMed lists PMID 39795193 in Molecules (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-01 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          10. Literature metadata

            Phenothiazine-Based Cu(II)-Selective Fluorescent Sensor: GHK-Cu Sensing Applications.↗

            PubMed lists PMID 37830186 in The Journal of organic chemistry as Journal Article, with publication-date metadata of 2023-10-13 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          11. Literature metadata

            Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.↗

            PubMed lists PMID 37896245 in Pharmaceutics as Journal Article, with publication-date metadata of 2023-10-18 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          12. Literature metadata

            In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer.↗

            PubMed lists PMID 31815212 in ACS omega as Journal Article, with publication-date metadata of 2019-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗

            U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

          2. 2
            Copper tripeptide-1 substance identity record ↗

            FDA Global Substance Registration System · Official source · Source checked July 29, 2026

          3. 3
            Certain bulk drug substances for use in compounding that may present significant safety risks ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          4. 4
            Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (1994) · PMID 17147644 ↗

            Wound Repair and Regeneration · Official source · Source checked November 14, 2026

          5. 5
            Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006) · PMID 16847171 ↗

            Archives of Facial Plastic Surgery · Official source · Source checked November 14, 2026

          6. 6
            Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

            Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

          7. 7
            HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

            U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026